Consolidated Condensed Statements of Cash Flows
Nine Months Ended |
||||
(In Millions; Unaudited) |
Sep 30, 2023 |
Oct 1, 2022 |
||
Cash and cash equivalents, beginning of period |
$ 11,144 |
$ 4,827 |
||
Cash flows provided by (used for) operating activities: |
||||
Net income (loss) |
(985) |
8,678 |
||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||
Depreciation |
5,753 |
8,309 |
||
Share-based compensation |
2,433 |
2,392 |
||
Restructuring and other charges |
718 |
665 |
||
Amortization of intangibles |
1,336 |
1,439 |
||
(Gains) losses on equity investments, net |
47 |
(4,075) |
||
(Gains) losses on divestitures |
- |
(1,072) |
||
Changes in assets and liabilities: |
||||
Accounts receivable |
1,290 |
1,991 |
||
Inventories |
1,758 |
(2,043) |
||
Accounts payable |
(1,082) |
(485) |
||
Accrued compensation and benefits |
(1,171) |
(1,912) |
||
Income taxes |
(2,676) |
(4,062) |
||
Other assets and liabilities |
(574) |
(2,095) |
||
Total adjustments |
7,832 |
(948) |
||
Net cash provided by (used for) operating activities |
6,847 |
7,730 |
||
Cash flows provided by (used for) investing activities: |
||||
Additions to property, plant, and equipment |
(19,054) |
(19,145) |
||
Purchases of short-term investments |
(37,287) |
(31,669) |
||
Maturities and sales of short-term investments |
36,725 |
35,129 |
||
Sales of equity investments |
375 |
4,880 |
||
Proceeds from divestitures |
- |
6,579 |
||
Other investing |
518 |
(2,764) |
||
Net cash used for investing activities |
(18,723) |
(6,990) |
||
Cash flows provided by (used for) financing activities: |
||||
Repayment of commercial paper |
(3,944) |
- |
||
Payments on finance leases |
(96) |
(341) |
||
Partner contributions |
1,106 |
- |
||
Proceeds from sales of subsidiary shares |
2,423 |
- |
||
Issuance of long-term debt, net of issuance costs |
11,391 |
6,103 |
||
Repayment of debt |
(423) |
(3,088) |
||
Payment of dividends to stockholders |
(2,561) |
(4,488) |
||
Other financing |
457 |
776 |
||
Net cash provided by (used for) financing activities |
8,353 |
(1,038) |
||
Net increase (decrease) in cash and cash equivalents |
(3,523) |
(298) |
||
Cash and cash equivalents, end of period |
$ 7,621 |
$ 4,529 |